MedTrace Logo

Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1

NCT00015028 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-01-16

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment. The developmental objective for this combination product is an expansion of therapeutic options for the treatment of opiate dependence.

Conditions

  • Opioid-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Buprenorphine/naloxone

Sponsors & Collaborators

  • Cincinnati MDRU

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Eugene Somoza, M.D., Ph.D. · Cincinnati MDRU

Study Design

Purpose
TREATMENT

Eligibility

Min Age
23 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-11-30
Primary Completion
1996-12-31
Completion
1997-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00015028 on ClinicalTrials.gov